ÂÜÀòÂÒÂ×

Richard Davis serves as Chief Operating Officer and Chief Business Officer at Nouscom AG since October 2020, and is a Non-Executive Director at Nanexa AB, which specializes in long-acting injectable drugs. Prior experience includes a role as Senior Director and Global Oncology Transaction Lead at Johnson & Johnson from October 2016 to September 2020, and as Chief Executive Officer at Trino Therapeutics, a company focused on treatments for inflammatory bowel disease. Richard Davis held the position of Direct Healthcare Investor at Wellcome Trust from March 2005 to September 2014, where responsibilities included managing pharmaceutical investments and overseeing the establishment of a significant early-stage pharmaceutical corporate venture fund. The career began with more than six years as Principal Scientist at Pharmagene, contributing to operational and business development efforts. Richard Davis earned a PhD in Pharmacology/Biochemistry from the University of Leicester.